Back to Top Skip to main content Skip to sub-navigation

Military Health System participating in COVID-19 vaccine trial

Woman measuring out a vaccine into a needle Five military medical treatment facilities are participating in a Phase 3 clinical trial testing a COVID-19 vaccine in development with AstraZeneca. (Photo by Air Force Staff Sgt. Joshua Garcia.)

Recommended Content:

Coronavirus | COVID-19 Vaccine Efforts | COVID-19 Vaccine Toolkit | Vaccine Trials

Five military medical treatment facilities in the National Capital Region, Texas, and California are participating in a phase 3 clinical trial testing the AstraZeneca COVID-19 vaccine in development under Operation Warp Speed.  The DoD sites are actively enrolling study participants, with a goal to recruit up to 1,000 volunteers in each of the three market areas towards the total AstraZeneca clinical trial enrollment of 30,000 people.

Operation Warp Speed, a multiagency U.S. Government effort led by the Department of Health and Human Services and the Department of Defense, is working with the private sector with the aims to deliver safe and effective COVID-19 vaccine doses to the American public beginning January 2021.

OWS is funding clinical trials evaluating several vaccine candidates which were selected based on promising data on safety, immune response, and protection in animal studies and safety and immune response data in early-stage trials in humans. Each of the trials is designed to collect data on how well a vaccine candidate protects against COVID-19 and on the safety of the vaccine candidate in a larger population, including people most at risk.  

“The Department of Defense continues to play a key role in the development of a potential COVID-19 vaccine,” said Thomas McCaffery, assistant secretary of Defense for Health Affairs. “Now that vaccines have passed the first phases of testing for safety, dosing, and response, we have moved into the next phase where volunteers are needed to join large clinical studies. We are excited to have several sites supporting these next steps in the vaccine development process.”

Large phase 3 clinical trials are a necessary part of the rigorous scientific process to test the efficacy and safety of a vaccine in a real-world setting with a large population sample, said Air Force Col (Dr.) Jessica Cowden, chief medical officer of the DoD Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense Enabling Biotechnology Vaccine Acceleration Project.

“Phase 3 studies are designed to evaluate if the vaccine can prevent disease in the populations of people that the vaccine is being developed to protect,” said Cowden. “Phase 3 studies are large and usually involve some people who are at risk for infection and disease.”

The National Institute of Allergy and Infectious Diseases at the National Institutes of Health established a network of infectious disease experts and research partners, termed the Coronavirus Prevention Network, or CoVPN, to rapidly and thoroughly evaluate U.S. government-sponsored COVID-19 vaccines. The CoVPN website (https://www.coronaviruspreventionnetwork.org/) provides general information about products being developed to prevent COVID-19 and about clinical trials.

According to the CoVPN, interested volunteers must be adults aged 18 and older to be screened for these initial trials. The CoVPN recognizes the importance of including volunteers who are more likely to get COVID-19, such as those over the age of 65 or with underlying medical conditions; as well as people who work in an essential job, live in a densely populated area, or represent a racial and ethnic group greatly impacted by the epidemic.

Representation by such groups matters in Phase 3 trials because vaccines need to be tested in populations who are at most risk of being exposed to the disease and getting sick in the real world, explained Cowden. “At-risk populations shouldn’t bear a disproportionate burden of research, but they need to be represented,” she said

The selected DoD sites are currently enrolling volunteers for the AstraZeneca clinical trial, according to Cowden. The trial is a randomized control, double-blind study, meaning volunteers will either receive the study vaccine or saline. “The study team and the participant will be blinded so that they won’t know which the participant received until the end of the study,” Cowden said. AstraZeneca’s vaccine candidate is in late-stage clinical trials ongoing in the U.K., Brazil and South Africa.

“Participating in a vaccine clinical trial is voluntary but is also critically vital to ensure that the overall effort is ultimately successful,” said Dr. Sean Biggerstaff, acting deputy director, DHA Research and Development Directorate. “Volunteers should also know safety remains an overriding priority for anyone participating in clinical trials.”

Military health beneficiaries who wish to volunteer for the AstraZeneca COVID-19 vaccine at a nearby military medical treatment facility (or at a civilian site close to home) can contact the local study team directly to request more information or can register on the CoVPN website and consent to be contacted by a research team. If registering on the CoVPN site, interested volunteers should enter the appropriate code in parenthesis from the list below, or enter their ZIP code to join the registry. Site contact information is included here:

At this point, the DoD is only participating in the AstraZeneca study. Additional DoD sites are being prepared for participation in other clinical trials of vaccines and monoclonal antibodies to prevent COVID-19, said Cowden.

“Having a safe and effective COVID-19 vaccine is what we need to protect people and get life back to normal, but in order to get to that point, we have to do these clinical trials,” explained Cowden. “These big Phase 3 clinical trials with a lot of people participating are critical so we can get the information we need to determine if a vaccine candidate is safe and can prevent COVID-19.”

You also may be interested in...

COVID-19 Vaccine Leader Card

Publication
5/27/2021

This printable card provides talking points when discussing the COVID-19 vaccine with servicemembers who are reluctant or indifferent to accepting the vaccine. The card lists common concerns and impressions, top 5 key messages, and supporting facts about the vaccine.

Recommended Content:

COVID-19 Vaccine Toolkit | Get to Know the COVID-19 Vaccines | COVID-19 Vax Facts

Town Hall May 26 2021

Video
5/26/2021
Town Hall May 26 2021

RADM Anne Swap will discuss the National Capital Region's response to COVID-19

Recommended Content:

COVID-19 Vaccine Toolkit | Coronavirus | National Capital Region Market

Got Your 6 - May 26, 2021

Video
5/26/2021
Video screen image for the May 26, 2021 Got Your Six video

"Got Your 6" is TRICARE's COVID-19 vaccine video series that delivers important information and updates, three times a month. It includes the latest information about DoD vaccine distribution, the TRICARE health benefit, and vaccine availability for a DoD-affiliated, and TRICARE beneficiary audience.

Recommended Content:

MHS Toolkits and Branding Guidance | MHS Toolkits and Branding Guidance | COVID-19 Vaccine Efforts | COVID-19 Vaccine Toolkit

COVID-19 Town Hall with RADM Anne M. Swap

Article
5/24/2021
MHS and Military OneSource NCR COVID-19 Town Hall with Rear Admiral Anne M. Swap, Director, National Capital Medical Directorate, Wednesday, May 26 at 11:50 a.m. ET

The purpose of this event is to inform National Capital Region (NCR) beneficiaries of DHA’s efforts with battling coronavirus (COVID-19) and encourage them to not delay care.

Recommended Content:

COVID-19 Vaccine Toolkit | Coronavirus | COVID-19 Vaccine Efforts | MHS and Military OneSource To Your Health

Unit Leader Vaccine Conversation Guide

Publication
5/24/2021

This guide offers approaches and illustrative examples for preparation, delivery, and navigation of small group discussions (recommended 1-5 people to facilitate greatest engagement) with servicemembers reluctant or indifferent to accepting the vaccine. The guide promotes an open dialogue regarding vaccine hesitancy and complacency by addressing concerns, building trust, and boosting vaccine confidence.

Recommended Content:

COVID-19 Vaccine Toolkit | Get to Know the COVID-19 Vaccines | COVID-19 Vax Facts

Provider Vaccine Conversation Guide

Publication
5/24/2021

This guide offers approaches and illustrative examples for Military Health System (MHS) providers to discuss the COVID-19 vaccine with servicemembers during routine visits. Initiating a COVID-19 vaccine conversation during servicemember visits will allow you to effectively address concerns, build trust, and boost vaccine confidence.

Recommended Content:

COVID-19 Vaccine Toolkit | Get to Know the COVID-19 Vaccines | COVID-19 Vax Facts

Adirim, Place laud DHA response to COVID-19 in briefing

Article
5/21/2021
Defense Health Agency Director Lt. Gen. (Dr.) Ronald J. Place speaking at a press conference

Dr. Terry Adirim, acting assistant secretary of defense for health affairs, and Army Lt. Gen. (Dr.) Ronald J. Place, director of the Defense Health Agency, provided a COVID-19 update during a Pentagon press briefing.

Recommended Content:

COVID-19 Vaccine Toolkit | Coronavirus

Sailors continue to receive COVID-19 vaccine

Article
5/20/2021
Military personnel wearing a face mask receiving the COVID-19 vaccine

Sailors continue to voluntarily receive one of the three available COVID-19 vaccines.

Recommended Content:

COVID-19 Vaccine Toolkit | Coronavirus | COVID-19 Vaccine Efforts

Vax Facts: I'm fully vaccinated. What can I do?

Video
5/20/2021
DHA Seal

If you're fully vaccinated, there are options for safer activities. Watch to learn what activities you can resume once you're fully vaccinated.

Recommended Content:

COVID-19 Vaccine Toolkit | COVID-19 Vaccine Efforts

Vax Facts: Risk and Precautions

Video
5/20/2021
DHA Seal

If you're fully vaccinated, there are options for safer activities. Watch to learn what activities you can resume once you're fully vaccinated.

Recommended Content:

COVID-19 Vaccine Toolkit | COVID-19 Vaccine Efforts

Vax Facts: Recommendations for Pregnancy

Video
5/20/2021
DHA Seal

The COVID vaccine is recommended for pregnant people. Watch to learn how your doctor can help you make the best decision for you and your baby.

Recommended Content:

COVID-19 Vaccine Toolkit | COVID-19 Vaccine Efforts

Vax Facts: How Long Does Protection Last

Video
5/20/2021
DHA Seal

We're not sure how long you're protected against COVID, although researchers are continuing to study the vaccine. Watch to learn how to get updates on how long your protection lasts.

Recommended Content:

COVID-19 Vaccine Toolkit | COVID-19 Vaccine Efforts

COVID Vax Fact Children Get Vaccine

Infographic
5/19/2021
that the Pfizer vaccine is approved for children ages 12 to 15 and that children should be vaccinated. Graphic includes the TRICARE logo on the bottom right, and outlines of medical related items on the left of the page. Links include www.tricare.mil/COVIDVaccine

Graphic saying that the Pfizer vaccine is approved for children ages 12 to 15 and that children should be vaccinated. Graphic includes the TRICARE logo on the bottom right, and outlines of medical related items on the left of the page.

Recommended Content:

COVID-19 Vaccine Toolkit | COVID-19 Vax Facts

MHS quickly adapted to improve patient experience during pandemic

Article
5/19/2021
Military health personnel waiting for the next phone call on the COVID-19 advice line

MHS adapted technology to boost patient experience during pandemic

Recommended Content:

COVID-19 Vaccine Toolkit | Coronavirus

DHA Director visits MCAGCC to hear from the ‘Boots on the Ground’

Article
5/19/2021
Military personnel wearing face masks walking

DHA Director visits Marine Corps Air Ground Combat Center Twentynine Palms.

Recommended Content:

MHS GENESIS | Military Health System Transformation | Coronavirus | COVID-19 Vaccine Toolkit
<< < ... 6 7 8 9 10  ... > >> 
Showing results 76 - 90 Page 6 of 43

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.